Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy

Annals of Surgical Oncology

Volumn 21, Issue 6, 2014, Pages 2083-2090

  Lee, Hyebin ^a   Ahn, Yong Chan ^a   Pyo, Hongryull ^a   Kim, Bokyong ^a   Oh, Dongryul ^a   Nam, Heerim ^a   Lee, Eunju ^a   Sun, Jong Mu ^a   Ahn, Jin Seok ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a   Choi, Yong Soo ^a   Kim, Jhingook ^a   Zo, Jae Ill ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Lymph node; Non small cell lung cancer; Prognostic factor; Stage IIIA; Trimodality therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; LUNG INFECTION; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PLEURA EMPYEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; SENESCENCE; SURGICAL MORTALITY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT THERAPY; ADOLESCENT; AGE; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MEDIASTINUM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902180288     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3540-x     Document Type: Article

References (23)

1. Martini N, Flehinger BJ, Zaman MB, Beattie EJ Jr. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg. 1983;198:386-397.
2. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
3. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
4. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874-1881.
5. Martini N, Kris MG, Ginsberg RJ. The role of multimodality therapy in locoregional non-small cell lung cancer. Surg Oncol Clin N Am. 1997;6:769-791.
6. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452-1460.
7. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-5917.
8. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992;53:992-998.
9. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2012;30:172-178.
10. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880-1892.
11. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 1997;15:712-722.
12. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
13. Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012;93:1807-1812.
14. Toyooka S, Kiura K, Shien K, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;15:954-960.
15. Ahn YC, Park K, Kim DY, et al. Preoperative concurrent chemoradiotherapy for stage IIIA non-small cell lung cancer. Acta Oncol. 2001;40:588-592.
16. Kang MK, Ahn YC, Lim DH, et al. Preoperative concurrent radiochemotherapy and surgery for stage IIIA non-small cell lung cancer. J Korean Med Sci. 2006;21:229-235.
17. Kim KJ, Ahn YC, Lim do H, et al. (2007) Analyses on prognostic factors following tri-modality therapy for stage IIIa non-small cell lung cancer. Lung Cancer. 55:329-336.
18. NCCN guidelines version 2. 2013. Non-small cell lung cancer. Available from http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. 2013.
19. Machtay M, Lee JH, Stevenson JP, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response. J Thorac Cardiovasc Surg. 2004;127:108-113.
20. Pourel N, Santelmo N, Naafa N, et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg. 2008;33:829-836.
21. D'Angelillo RM, Trodella L, Ciresa M, et al. Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol. 2009;4:1517-1523.
22. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18:2981-2989.
23. Tanner NT, Gomez M, Rainwater C, et al. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012;7:365-369.